EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Participation of B cell in immunotherapy of cancer

Nikhil Chandnani, Ishika Gupta, Ayush Mandal, Koustav Sarkar

Pathology - Research and Practice · 2024

DOI: 10.1016/j.prp.2024.155169 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Nikhil Chandnani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India. Hauptthemen laut MEDLINE: Tertiary Lymphoid Structures, Neoplasms. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: Science and Engineering Research Board, Department of Science and Technology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Even though their effector roles extend beyond conventional humoral immunity, B and plasma cells may exhibit antitumor effects through antibody-dependent cell cytotoxicity (ADCC) and activation of the complement cascade. Depending on whether they are positioned in immature or mature compartments termed tertiary lymphoid structures (TLS), which include T cells, B cells are believed to play numerous functions in modulating the immune system's capacity to destroy cancer cells. These formations represent a process of lymphoid neogenesis that takes place in peripheral tissues in response to prolonged exposure to inflammatory signals. Activated in the germinal centres of tertiary lymphoid structures, B cells may directly present tumor-associated antigens to T cells, make antibodies that enhance antigen presentation to T cells, or kill tumour cells, resulting in a favourable therapeutic effect. Immune complexes may also enhance inflammation, angiogenesis, and immunosuppression via the activation of macrophages and complement, resulting in detrimental effects. The functional variety of B-cell subsets includes professional antigen-presenting cells, regulatory cells, memory populations, and plasma cells that produce antibodies. Importantly, antibodies may independently generate innate immune responses and the cancer immunity cycle. B cells and B-cell-mediated antibody responses constitute the largely underestimated second arm of the adaptive immune system and unquestionably need more consideration in cancer. This article reviews the known roles of B lymphocytes in the tumour microenvironment, their contribution to anticancer activity of immunotherapies, and their significance in overall survival of cancer patients. In addition to producing antibodies, B cells regulate the immune system and serve as effective antigen-presenting cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tertiary Lymphoid StructuresNeoplasmsHumansB-LymphocytesT-LymphocytesAntibodiesImmunotherapyTumor Microenvironment

Stichwörter der Autor:innen

ADCCAPCB cellHumoral immunityTumour cells

Substanzen

Antibodies

Autor:innen und Institutionen

  • Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India.
  • Department of Biotechnology, SRM Institute of Science and Technology, Kattankulathur, Tamil Nadu 603203, India. Electronic address: koustavsarkar@gmail.com.

Förderung

  • Science and Engineering Research Board
  • Department of Science and Technology, Ministry of Science and Technology, India

Zitieren

APA

Chandnani, N., Gupta, I., Mandal, A., & Sarkar, K. (2024). Participation of B cell in immunotherapy of cancer. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155169

Vancouver

Chandnani N, Gupta I, Mandal A, Sarkar K. Participation of B cell in immunotherapy of cancer. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155169

BibTeX
@article{Chandnani2024,
  author = {Chandnani, Nikhil and Gupta, Ishika and Mandal, Ayush and Sarkar, Koustav},
  title = {Participation of B cell in immunotherapy of cancer},
  journal = {Pathology - Research and Practice},
  year = {2024},
  doi = {10.1016/j.prp.2024.155169}
}
Kostenlos starten →